New Simeprevir data will be presented at The International

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Mar 24, 2014 at 5:30 AM

New Simeprevir data will be presented at The International Liver Congress 2014 of the European Association for the Study of the Liver, (EASL)

· Presentations Include late-breaking final results from the phase II COSMOS study Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that new data from the clinical development program for simeprevir in the treatment of genotype 1 or genotype 4 chronic hepatitis C virus (HCV) in adult patients with compensated liver disease will be presented at The International Liver Congress of the European Association for the study of the Liver (EASL). The International Liver Congress 2014 will take place from April 9-13 in London, United Kingdom. Eight oral and poster presentations spanning over the phase II and phase III development program for simeprevir in treatment combinations with and without ribavirin and interferon are planned. New analyses of data from the phase III QUEST-1, QUEST-2 and PROMISE clinical trials of simeprevir in combination with pegylated interferon and ribavirin, as well as final data from the phase II COSMOS study will be presented during the Congress. The data to be presented at the International Liver Congress 2014 include: Late-Breaking Presentations · Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype 1 prior null-responder/treatment-naïve patients (COSMOS Study): primary endpoint (SVR12) results in patients with METAVIR F3-4 (Cohort 2) - Lead Author: Eric Lawitz; The Texas Liver Institute, University of Texas Health Science Center, San Antonio, USA · Once-daily simeprevir (TMC435) with peginterferon/ribavirin in treatment -naïve or treatment-experienced chronic HCV genotype-4 infected patients: SVR12 results of a Phase 3 trial (RESTORE Study) - Lead Author: Christopher Moreno; ULB Hôpital Erasme, Brussels, Belgium Oral Presentations · Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 prior null responders with METAVIR F0-2: COSMOS Study Cohort 1 subgroup analysis - Lead Author: Mark Sulkowski; Johns Hopkins University School of Medicine, Baltimore, USA · Simeprevir with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in European patients who relapsed after previous interferon -based therapy: the PROMISE trial - Lead Author: Xavier Forns; Liver Unit, Hospital Clinic, Barcelona, Spain Poster Presentations · Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve European patients in the QUEST-1 and QUEST-2 Phase 3 trials - Lead Author: Graham R. Foster; Queen Mary’s, University of London, London, UK · Simeprevir reduces time with peginterferon/ribavirin-induced symptoms and quality-of-life impairments: 72-week results from three Phase 3 studies - Lead Author: Jane Scott; Janssen · Virology analyses of simeprevir in Phase 2b and 3 studies - Lead Author: Oliver Lenz; Janssen · Deep sequencing analyses of minority baseline polymorphisms and persistence of emerging mutations in HCV genotype 1-infected patients treated with simeprevir - Lead Author: Bart Fevery; Janssen Full session details and data presentation listings for The International Liver Congress 2014 can be found at http://www.ilc-congress.eu. For more information please contact: Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292 Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 10.15 CET on 24 March 2014. About Simeprevir Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB and indicated for the treatment chronic hepatitis C infection in combination with pegylated interferon and ribavirin in HCV genotype 1 and 4 infected patients with compensated liver disease, including cirrhosis. Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB will retain marketing rights for simeprevir in these countries under the marketing authorization held by Janssen-Cilag International NV. The treatment was approved for the treatment of genotype 1 hepatitis C in September 2013 in Japan and in November 2013 in Canada and the U.S. and in March 2014 in Russia. The Committee for Medicinal Products for Human Use (CHMP) recently recommended Marketing Authorisation in the European Union for the use of simeprevir in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients. An approval is expected during Q2-2014. About Medivir Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is being developed in collaboration with Janssen R&D Ireland. The company is also working with research and development in other areas, such as bone disorders and neuropathic pain. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

KT&G Soars with Record Profits, Aggressive Share Buybacks

KT&G Climbs to New Heights with Record-Setting Q3 If you're eyeballing the markets like a hawk, KT&G (KRX: 033780) just gave you something to squawk about. In the world of stocks, milestones are few and far between, but KT&G is handing out milestones like candy in Q3. They rolled out their numbers for the quarter, and let me tell ya, this was no pie-in-the-sky nonsense....

Rescue Uncovers Dark Realities in Chinchilla Trade

Desperate Conditions for Ohio Chinchillas Walking into an animal breeding facility should never feel like stepping into a house of horrors, yet that’s exactly what rescuers from Humane World for Animals encountered. The grim scene unfolded in Jenera, Ohio, where nearly 1,000 chinchillas were discovered in appalling conditions. After years of violations under the Animal...

GaNrich: Gallium Nitride Game-Changer Expands Global Reach

Rattling the Silicon Cage: GaNrich's Transformative Climb Well, folks, here's a story that makes even the most stoic traders sit up and take notice: GaNrich Semiconductor, a Taiwan-based trailblazer, is serving a wallop to the traditional silicon power device monopoly. By expanding their GaN power device portfolio to cover voltages ranging a whopping 40V to 1200V, GaNrich...

Construction Partners' Georgia Move Bolsters Growth

CPI's Strategic Expansion into Georgia Here's an acquisition to keep your eye on: Construction Partners, Inc. (NASDAQ: ROAD), also known in the corridors of trading as CPI, is making a move that many of us in the business have been anticipating for some time. They’ve wrapped up the acquisition of Piedmont Paving, Inc., a Newnan, Georgia-based company. Now, for most...

Vermiculus Taps New CISO Amid Index Engine Launch

Vermiculus Ups Its Security Game You ever wonder why a company decides to beef up security? Well, Vermiculus ain't leaving anything to chance as they roll out new tech. They've named Alexander Kilian the Chief Information Security Officer. Yep, Kilian's stepping into the ring, and no one’s treating this like a sidebar gig. This market tech outfit isn't just polishing...

Ondo Finance Tops Tokenization with $4B Milestone

Ondo Finance Claims Tokenization Throne Damn, if you thought tokenization was just a sideshow in the fintech carnival, think again. Ondo Finance has waltzed its way to the front of the line, claiming the heavyweight title with over $4 billion in tokenized real-world assets. That's right, folks—$4 billion in the bag, handily surpassing 202 other platforms with its...

Dissecting the USDOT's New DBE/ACDBE Final Rule

The Landscape Shift in DBE/ACDBE Compliance When the USDOT decided to roll out their Final Rule in September, they didn't just shuffle the deck - they reshuffled the whole game for the Disadvantaged Business Enterprise (DBE) and Airport Concession Disadvantaged Business Enterprise (ACDBE) programs. Public agencies and businesses from coast to coast have been left...

Kyndryl and AWS Shake Up Enterprise Modernization

A New Dawn for Enterprise Modernization Modernizing enterprise infrastructure today ain't just about wading through outdated code lines. Kyndryl (NYSE: KD) is flipping the script, with their latest partnership with Amazon Web Services (AWS) aiming to make modernization swift, continuous, and AI-ready. Gone are the days of treating technology upgrades as a one-off event....

Alley Cat Allies Offers Largest Reward Ever in Cat Case

A Juicy Reward for Justice: The Tale of Trooper Imagine sitting in a quiet town, sipping coffee, when news breaks of an animal cruelty case that's got the whole place buzzing. Out in Conover, North Carolina, there's been a grim tale that’s now throwing spotlights on how we treat our furry companions. Trooper, a cat who couldn’t dodge the blowgun’s dart shot by some...

What's the Deal with Generations+ at P.C. Richard & Son? Felt like companies were giving away the farm just to keep customers hooked, and then I heard about P.C. Richard & Son's latest play. They've been around for a scorching 117 years, and now they're offering something they've never done before: a free membership program called Generations+ that tosses perks like candy...